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Ceramide analog  [18F]F‑HPA‑12 
detects sphingolipid disbalance 
in the brain of Alzheimer’s disease 
transgenic mice by functioning 
as a metabolic probe
Simone M. Crivelli1,2, Daan van Kruining1, Qian Luo1, Jo A. A. Stevens1, 
Caterina Giovagnoni1, Andreas Paulus3,4,5, Matthias Bauwens3,4, Dusan Berkes6, 
Helga E. de Vries7, Monique T. Mulder8, Jochen Walter9, Etienne Waelkens10, Rita Derua10, 
Johannes V. Swinnen11, Jonas Dehairs11, Felix M. Mottaghy3,4,5, Mario Losen1, 
Erhard Bieberich2,12 & Pilar Martinez‑Martinez1*
The metabolism of ceramides is deregulated in the brain of Alzheimer’s disease (AD) patients and is 
associated with apolipoprotein (APO) APOE4 and amyloid‑β pathology. However, how the ceramide 
metabolism changes over time in AD, in vivo, remains unknown. Distribution and metabolism of  [18F]
F‑HPA‑12, a radio‑fluorinated version of the ceramide analog N‑(3‑hydroxy‑1‑hydroxymethyl‑3‑
phenylpropyl) dodecanamide, was investigated in the brain of AD transgenic mouse models (FAD) on 
an APOE4 or APOE3 genetic background, by positron emission tomography and by gamma counter. 
We found that FAD mice displayed a higher uptake of  [18F]F‑HPA‑12 in the brain, independently from 
the APOE4 or APOE3 genetic background. FAD mice could be distinguished from littermate control 
animals with a sensitivity of 85.7% and a specificity of 87.5%, by gamma counter measurements. 
Metabolic analysis of  [18F]F‑HPA‑12 in the brain suggested that the tracer is degraded less efficiently 
in the FAD mice. Furthermore, the radioactive signal registered in the hippocampus correlated with 
an increase of Cer d18:1/20:2 levels measured in the same brain region by mass spectrometry. Our 
data gives additional proof that ceramide metabolism is different in FAD mice compared to controls. 
Ceramide analogs like HPA‑12 may function as metabolic probes to study ceramide disbalance in the 
brain.
Evidence correlating Alzheimer’s disease (AD) pathophysiology and altered ceramide metabolism, in the brain, 
is  increasing1–3. The global levels of specific ceramide species extracted from middle frontal gyrus, temporal 
gyrus, inferior parietal lobe, and hippocampus are elevated in AD patients compared to healthy  controls4–6. 
Whether these observations pertaining to the pathophysiology of AD are causative or a subsequent event, is 
still unclear. Nevertheless, recent clinical and preclinical literature points to prodromal changes in ceramide 
metabolism in  AD7. Long-chain ceramide species, like Cer d18:1/22:0 or Cer d18:1/24:0, are elevated in plasma 
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before phenoconversion to mild cognitive impairment or  AD8–10. The levels of ceramide in cerebral spinal fluid 
correlates with the concentration of some forms of amyloid-β (Aβ), like Aβ1-38 and Aβ1-40, in individuals at 
high risk of developing AD. This suggests early involvement of ceramide in the pathogenesis of the  disease11,12. 
In alignment with these observations, some enzymes responsible for ceramide anabolic or catabolic synthesis 
are highly expressed and abnormally active in AD brain tissue, compared to healthy  controls13,14. Aβ peptides 
activate phosphodiesterases that break down sphingomyelin to produce ceramide in neurons and glial  cells15,16. 
The greatest genetic risk factor to develop AD, the apolipoprotein E4 (APOE4), interestingly enough, was associ-
ated with increased ceramide levels in the brain compared to APOE3 carriers in AD positive  cases17. Therefore, 
the discovery of tools which are designed to measure altered sphingolipid metabolism in the brain, in vivo, could 
be valuable to study ceramide disbalance in pathology and also aid in diagnosing neurodegeneration.
Ceramide transfer proteins (CERTs) are essential proteins of the sphingolipid  metabolism18–21. Following the 
synthesis of ceramide in the endoplasmic reticulum (ER), CERTs extract and relocate ceramide to the trans-Golgi 
where sphingomyelin (SM) is  synthesized22,23. CERTs have several functional domains involved in this process, 
including a steroidogenic acute regulatory protein (StAR)-related lipid transfer START domain, that binds to 
ceramide, a pleckstrin homology domain (PH) that recognizes Golgi phosphatidylinositol 4-monophosphate, 
and a two phenylalanines in an acidic tract (FFAT) motif that interacts with the ER-resident protein VAMP-
associated protein (VAP)24,25. When CERTs activity is blocked pharmacologically or compromised genetically 
by mutating the START domain, SM synthesis is reduced within  minutes26,27.
The synthetic ceramide analog N-(3-hydroxy-1-hydroxymethyl-3-phenyl propyl) dodecanamide (HPA-12) 
is a competitive inhibitor of CERTs transport function. HPA-12 displaces endogenous ceramide and occupies 
the amphiphilic cavity in the START domain of CERTs, preventing ceramide to be shuttled to the  Golgi27,28. We 
recently reported the pharmacokinetics and in vivo biodistribution of HPA-12 in wild type  animals29. We dem-
onstrated that the radiolabel analog,  [18F]F-HPA-12, enters the central nervous system (CNS) and accumulates, 
over time in the brain parenchyma without being completely  metabolized29. However, the possible use of  [18F]
F-HPA-12 in transgenic AD mouse models, was not explored to date. In this study we employed transgenic FAD 
mice with a mutated amyloid precursor protein (APP)/ presenilin 1 (PSEN1), carrying human APOE4 or APOE3 
 genes30. Littermates not carrying AD mutated genes APP/PSEN1 were used as controls.
In this study, we report that  [18F]F-HPA-12 accurately differentiates APP/PSEN1 transgenic animals from 
control animals with a sensitivity of 85.7% and a specificity of 87.5%. This confirms a sound connection between 
ceramide metabolism and Aβ pathology. However, the tracer did not detect sphingolipid disbalance specifically 
driven by the APOE4 genes. We propose that differences in radiotracer uptake is due to slower degradation of 
the tracer in FAD mouse models.
Results
Sphingolipid disbalance in FAD (E3FAD, E4FAD) compared to control (APOE3, APOE4) 
mice. Amyloid pathology progression, neuroinflammation, and behavioral deficits have been partly described 
before in E3FAD and  E4FAD30–32. Meanwhile, the impact of APOE4 on sphingolipid metabolism in the brain is 
still unexplored. Therefore, we addressed the effect of APOE4 background on sphingolipid metabolism by liquid 
chromatography-electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS) analysis on hippocampal 
tissue of 8 to 9-month-old female mice.
To uncover sphingolipid metabolic differences between APOE3, APOE4, E3FAD, and E4FAD, we performed 
the first level of analysis by creating a heatmap based on the relative mean quantity of the following sphingolipid 
classes: ceramides, SM, dihydroceramide, and monohexyl-ceramides (Fig. 1A–D). The hierarchical relationships 
between genotypes showed that ceramides were mostly different depending on the APOE background. However, 
the most significant dissimilarities between APOE3 and APOE4 carriers were in the monohexyl-ceramides which 
were elevated overall in the APOE4 background. Meanwhile, the impact of FAD genes were strong among the 
dihydroceramide and SM classes. The SM class was mostly reduced depending on specific acyl chain while the 
dihydroceramide species were overall elevated in FAD mice with some exceptions.
We further investigated the difference between genotypes by running a MANOVA for each of the 4 classes 
of sphingolipid with AD and APOE genes as fixed factors, to the same data set. Two sphingolipid classes gave 
significant MANOVA results for the ceramides and monohexyl-ceramide. The ceramides gave significant main 
effects of FAD genes (F = 846.210, p = 0.027; Wilks’ Lambda = 0.000084) and a statistically significant interac-
tion effect between FAD and APOE genes on the combined dependent variables (F = 368.123, p = 0.0401; Wilks’ 
Lambda = 0.000194). The Cer d18:1/20:2 was significantly elevated in FAD mice (F = 43.821, p = 0.000012). 
The interaction effects between FAD and APOE genes were confirmed in the following ceramide species Cer 
d18:0/16:0 and Cer d18:0/16:1 (F = 4.863, p = 0.045 and F = 4.969, p = 0.043 respectively) Fig. 2A. The sphin-
golipids Cer d18:0/16:0 and Cer d18:0/16:1 were both significantly reduced only in FAD mice with the APOE4 
background. The monohexyl-ceramides were exclusively affected by APOE genes (F = 14.657, p = 0.0242; Wilks’ 
Lambda = 0.0167). Seven (HexCer d18:1/14:0, HexCer d18:1/16:0, HexCer d18:1/16:1, HexCer d18:1/16:2, Hex-
Cer d18:1/18:1, HexCer d18:1/20:0 and HexCer d18:1/20:1) out of the twenty-two monohexyl-ceramide species 
analyzed were significantly elevated in the APOE4 background (F = 14.431, p = 0.002; F = 32.898, p = 0.00005; 
F = 12.2166, p = 0.0036; F = 8.940, p = 0.0097; F = 7.060, p = 0.0187; F = 4.970, p = 0.0432 and F = 14.2356, p = 0.0021 
respectively) Fig. 2B.
Astrocytic ceramide is a driver for Cer d18:1/20:2 elevation in the hippocampus. The reason as 
to why ceramide increases in both the brains of AD patients and AD animal models, is still unknown. However, 
transgenic animals with severe Aβ pathology show ceramide overproduction, suggesting that the reason is a con-
sequence of aberrant plaques formed in the brain. In addition, the idea that activated astrocytes may contribute 
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to ceramide elevation in the brain of AD patients, has recently been  reported33. Therefore, we tested these two 
hypotheses by quantifying plaques with Thioflavin S and astrocytes with anti-GFAP antibody staining in the hip-
pocampus (Fig. 3A,B) and correlated the measurements to Cer d18:1/20:2 levels (Fig. 3C). Co-immunostaining 
with anti-ceramide antibody indicated high co-localization with GFAP immuno-labeling (Fig. 3A). Quantifica-
tion of GFAP immunostaining presented a significant increase of astrocytes area in FAD compared to control 
(Student t test p = 0.0005) (Fig. 3B).
Correlation between the plaques area and Cer d18:1/20:2 levels were not significant (Fig. 3C). Instead, the 
association between astrocyte staining and Cer d18:1/20:2 levels, was significant (Fig. 3D).
This data suggests that activated astrocytes contribute to Cer d18:1/20:2 elevation in the hippocampus.
Brain uptake of  [18F]F‑HPA‑12 is increased in FAD mice compared to control mice. We previ-
ously demonstrated that the radio-fluorinated version of the ceramide analog  [18F]F-HPA-12, crosses the blood–
brain barrier and accumulates in the brain without being completely metabolized. However, we did not explore 
applications of the radioligand in disease conditions where sphingolipid metabolism is abnormal.[18F]F-HPA-12 
(injected dose per animal on average 1.8 MBq), was administered into the tail vein, and animals were scanned for 
1 h. The PET images displayed an increase in radioactive signal in the brain of FAD animals independently from 
the APOE4 or APOE3 backgrounds (Fig. 4A). Particularly, the hippocampus uptake was different between the 
control and FAD (Supplementary Fig. 1A). When analyzing the SUV, computed at 60 min, the FAD genotypes 
did not show statistically significant differences (Fig. 4B). However, the time-activity curves (TACs) revealed 
that the accumulation of the radiotracer in the brain parenchyma of the FAD animals was greater than in the 
control group (Fig. 4C). The comparison between the two curves was carried out comparing the Vmax and Km 
of the best fit values calculated with the Michaelis–Menten kinetic model (control Vmax = 0.4548 ± 0.0233; AD 
Vmax = 0.5558 ± 0.0245 and control Km = 0.6015 ± 0.5120; AD Km = 1.197 ± 0.5513; p = 0.0039).
Next, we performed autoradiography and biodistribution to confirm in vivo brain kinetics. 1.5 h post-injec-
tion the half brain was sagittally cryosectioned and mounted on glass for autoradiography. This confirmed a 
higher radio signal in the brain parenchyma of FAD mice brain with different intensities depending on brain 
region (Fig. 4D). The other brain hemisphere was micro-dissected into the brain stem, cerebellum, cortex, 
hippocampus, striatum, and bulbus, and analyzed by a gamma counter. The gamma counter measurements 
confirmed a higher uptake of  [18F]F-HPA-12 in FAD than in control animals (MANOVA with genotype as inde-
pendent factor F test = 3.569, Wilks Lambda value = 0.3393 and with p = 0.033) (Fig. 4E). Overall, the hippocam-
pus, striatum and bulbus retained significantly higher levels of the radiotracer (two-way ANOVA respectively 
F = 7.4164, p = 0.0164; F = 7.4164, p = 0.0396 and F = 6.3690, p = 0.0243).
Figure 1.  Heatmaps of sphingolipid levels in control (APOE3 and APOE4) and FAD (E3FAD and E4FAD) 
mice. Ceramide (A), Sphingomyelin (B), Dihydroceramide (C) and Monohexosylceramide (D) levels of the 
hippocampus were measured by LC-ESI/MS/MS. The heat maps show the fold difference (log 2 transformed) of 
the mean of the relative abundance of each sphingolipid quantified, with a dendrogram showing the hierarchical 
relationship between the genotypes: APOE3 N = 3, APOE4 N = 6, E3FAD N = 4 and E4FAD N = 5 (data shown as 
means transformed logarithmically). Within each lipid class, lipid species were hierarchically clustered.
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To determine how accurately  [18F]F-HPA-12 could distinguish the FAD mice from controls, we ran a Receiver 
Operating Characteristic (ROC) curve analysis with hippocampus biodistribution expressed in ID% / g (Area: 
0.9286; Standard deviation: ± 0.0745; 95% confidence interval: 0.7824 to 1.075; **p = 0,0055)34. The tracer with a 
cut off > 0.8135 had a sensitivity (the ability of the tracer to identify FAD mice correctly) of 85.7% and a specificity 
(the ability of the tracer to identify control animals correctly) of 87.5% (Fig. 4F). The positive likelihood ratio 
(+ LR = 6.86) was greater than 1 indicating that the radiotracer brain uptake is associated with AD pathology.
[18F]F‑HPA‑12 peripheral organ biodistribution. [18F]F-HPA-12 uptake was studied in the following 
organs: blood, heart, liver, kidneys, lungs, intestine, spleen, muscle, stomach, and bone (Fig.  5). No signifi-
cant differences were observed after MANOVA testing combining all the peripheral organ analyzed. However, 
the univariates analysis for lungs, intestine, and spleen had different uptake depending on APOE background. 
In all 3 of these organs, APOE4 carriers had larger uptake of the tracer (two-ANOVA respectively F = 6.7306, 
p = 0.0212; F = 11.7119, p = 0.004 and F = 4.6099 p = 0.0498). Only the muscle among peripheral organs showed a 
main effect of AD genes (F = 6.2391, p = 0.0255).
Figure 2.  The Cer d18:0/20:2 is increased in FAD mice while Cer d18:1/16:0 and Cer d18:1/16:0 are reduced 
only in FAD mice carrying APOE4. (A) Ceramides were quantified by LC-ESI/MS/MS and the relative 
abundance of each species was analyzed by MANOVA model with the AD and APOE genes as fixed factors. 
Among the analyzed ceramides Cer d18:0/20:2 showed the main effect of AD genes while Cer d18:1/16:0 
the main effect of APOE genes. Cer d18:1/16:0 and Cer d18:1/16:1 showed a significant interaction effect 
between AD and APOE genes. (B) Monohexosyl-ceramides were quantified by LC-ESI/MS/MS and the relative 
abundance of each species was analyzed by MANOVA model with the AD and APOE genes as fixed factors. 
Among the analyzed monohexosyl ceramides HexCer d18:1/14:0, HexCer d18:1/16:0, HexCer d18:1/16:1, 
HexCer d18:1/16:2, HexCer d18:1/18:1, HexCer d18:1/20:0 and HexCer d18:1/20:1 showed the main effect of 
APOE genes. Bars represent the mean ± SEM of control (APOE3 N = 3; APOE4 N = 6) and FAD (E3FAD N = 4; 
E4FAD N = 5) (*p < 0.05, ***p < 0.001).
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[18F]F‑HPA‑12 is metabolized differently in control than in FAD animals and correlates with 
Cer d18:1/20:2 levels but not with CERT levels in the hippocampus. We performed analytical 
studies by HPLC to measure differences in [18F]F-HPA-12 metabolism, between control and FAD animals, 
on urine, blood, and brains. Urine analysis in control mice indicated that 33% of the radioactivity levels were 
caused by free fluorine-18 (retention time 2–4 min), 66% by unknown metabolites (retention time 12–14 min), 
and 1% by  [18F]F-HPA-12 (retention time 16–18 min). In contrast, the percentage of FAD mice were respectively 
50%, 45%, and 5%, suggesting that especially unknown metabolites (retention time 12–14 min) are less present 
in AD animals. The blood analysis did not show differences in the levels of  [18F]F-HPA-12 and metabolites 
Figure 3.  Quantification of hippocampal astrogliosis correlates with Cer d18:0/20:2 levels. (A) Representative 
photomicrographs of nuclei (gray), plaques (green), GFAP (red) and ceramide (blue) fluorescent staining 
in CA1 region of the hippocampus of control and FAD mice. White arrow points to ceramide and GFAP 
co-localization (magenta). All photomicrographs were exposed and processed identically. Scale bar 100 µm. (B) 
Immunofluorescent quantification of GFAP measured by the percentage of area. Bars represent the mean ± SEM 
of control (APOE3 N = 2; APOE4 N = 2) and FAD (E3FAD N = 4; E4FAD N = 3). Student t test ***p < 0.001. 
(C) Correlation between: Cer d18:1/20:2 and plaques quantification expressed as percentage of area in the 
hippocampus Number of XY Pairs = 6. (D) Correlation between: Cer d18:1/20:2 and GFAP quantification 
expressed as percentage of area in the hippocampus. Number of XY Pairs = 10.
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between control and AD. Control animals displayed the following percentages: 10% of free fluorine-18 and 
metabolites, 7% of intact  [18F]F-HPA-12, 33% bound to plasma protein, and 50% associated with blood cells; 
while percentages of FAD mice were respectively 12, 6, 25 and 57%. In the brain, we found that  [18F]F-HPA-12 
was less degraded in AD brains compared to control (percentage of the intact compound in control = 26% and 
AD = 36%). Overall, the radio-analytical study suggested that  [18F]F-HPA-12 is degraded at a slower rate in AD 
compared to control animals due to the levels of intact  [18F]F-HPA-12, which were 5 times higher in the urine 
and 10% higher in the brain. De-fluorination could be excluded given the fact that the radioactive signal of the 
Figure 4.  Brain uptake of  [18F]F-HPA-12 is increased in FAD transgenic animals compared to controls. (A) 
Averaged sagittal and coronal brain slices from 47 to 60 min PET acquisition, co-registered with CT scan of 
control and AD animals. (B) Bar graphs of SUV computed at 60 min of PET acquisition. Bars represent the 
means ± SEM of data from control (APOE3 N = 3; APOE4 N = 6) and FAD (E3FAD N = 3; E4FAD N = 5). (C) 
Time activity curves (TACs) of control and AD brains expressed as standardized uptake value (SUV). The curves 
are the means ± S.E.M of data from n = 7–8 mice per experimental group. (D) Autoradiograms of control and 
FAD mice (APOE4 background). (E)  [18F]F-HPA-12 uptake 1.5 h post-injection in the brain stem, cerebellum, 
cortex, hippocampus, and bulbus. All values were normalized for tissue weight, radioactive decay, and injected 
dose (ID%/g). Bars represent the means ± SEM of control (APOE3 N = 3; APOE4 N = 6) and FAD (E3FAD N = 4; 
E4FAD N = 5) (two-way ANOVA, *p < 0.05). (F) ROC curve plotted with the true positive rate (Sensitivity %) 
in function of the false positive rate (100-Specificity %) for different cut-off points (criterion). Each point on 
the ROC curve (circles) represents a sensitivity/specificity pair corresponding to a decision threshold. In the 
random classification curve each point is noted with squares.
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bones, as measured by the gamma counter, was similar in all groups. Brain metabolism was further investigated 
using the fluorescent version of HPA-12 (HPA-12-NBD). The fluorescent group (NBD) was introduced in the 
sphingoid base of the compound, identical to the radionuclide version of HPA-12. Position C-12 is known to 
have no interference with the compound’s biological properties. One and a half hour post-intravenous injection, 
the fluorescent compound was extracted using the Folch method from hippocampal tissue and separated from 
its fluorescent metabolite by silica gel. The calculations of percentages of intact HPA-12-NBD indicated that the 
compound is found elevated in FAD, confirming the radio-analytical approach (Fig. 6A).
Next, to investigate if the increase of the radioactive signal found in the brain of AD animals was caused by an 
increase of CERT protein concentration, we quantified the transporter by enzyme-linked immunoassay (ELISA) 
in protein extract of the hippocampus. The results of the ELISA did not show any significant difference between 
the two genotypes (Fig. 6B). Moreover, while the concentration of CERTs in the hippocampus correlated with 
Cer d18:1/20:2 (Fig. 6C), it did not correlate with the radioactivity levels measured in the same region (Fig. 6D). 
Having said that, the radioactivity in the hippocampus correlated with Cer d18:1/20:2 which was significantly 
elevated in FAD mice (Fig. 6E) but not with astrogliosis (Fig. 6F).
Our data suggest that  [18F]F-HPA-12 is degraded faster in normal conditions compared to AD in the brain, 
and accumulation in the brain of the tracer is associated with Cer d18:1/20:2 levels in the brain tissue.
Discussion
Here, we report that the  [18F]F-HPA-12 dynamics, in vivo, is different in FAD mice brains compared to control. 
The statistical analysis revealed that the  [18F]F-HPA-12 uptake was faster and higher in the hippocampus, stria-
tum, and bulbus of AD animals. Metabolic analysis of the brain suggested that the higher levels of  [18F]F-HPA-12 
were due to a slower degradation of the tracer in the brain of FAD mice. Furthermore, while the radiotracer did 
not correlate with CERTs concentration in the hippocampus, it did correlate with Cer d18:1/20:2 levels, which 
were found to be significantly elevated in AD, in the same brain region.
The evidence associating the disruption of the sphingolipid metabolism to the molecular mechanisms under-
lying neurodegeneration is growing. A case in point is an increase of ceramide levels which has been described in 
Figure 5.  [18F]F-HPA-12 biodistribution analysis of peripheral organs.[18F]F-HPA-12 organ uptake 1.5 h 
post-injection in blood, heart, liver, kidney, lungs, intestine, spleen, muscle, stomach, and bone. All values were 
normalized for tissue weight, radioactive decay and injected dose (ID% / g). Bars represent the means ± SEM 
of control (APOE3 N = 3; APOE4 N = 6) and FAD (E3FAD N = 4; E4FAD N = 5) (two-way ANOVA, *p < 0.05; 
**p < 0.01).
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the brains of AD patients and the brains of transgenic mice displaying early onset of Aβ  pathology3. The proposal 
has been made in which ceramide plays a role in neuronal death by sensitizing neurons to Aβ toxicity and/or 
directly acting as a pro-apoptotic  messenger35,36. Besides, ceramide elevation might exacerbate neuroinflamma-
tion contributing to pathology  progression33. These multiple indications supported the proposal to modulate 
sphingolipid metabolism for the treatment of AD. The introduction of Fingolimod, a sphingosine-1-phosphate 
(S1P) analog known to modulate S1P  receptors37, for the treatment of multiple sclerosis further propelled the 
idea that drugs mimicking sphingolipid structure and bioactivity can be used to treat certain brain conditions. 
Therefore, establishing new methods to study sphingolipid disbalance in the brain could be valuable to better 
understand the role of ceramide in disease and discover new therapeutic approaches.
It is thought that sphingolipid and other families of lipids like cholesterol are linked to the amyloid pathology 
via three mechanisms: (i) increasing Aβ production by interfering with proteolytic activity of β-secretase and 
γ-secretase, (ii) facilitating Aβ aggregation by direct interaction with the lipid and (iii) mediating Aβ toxicity 
acting as second messengers or contributing to oxidative  stress5,38–40. Preclinical studies on genetic mouse models 
of AD suggest that amyloid pathology is accompanied by ceramide disbalance in the brain of these transgenic 
 mice36,41. However, as we previously reviewed it depends on genetic background and sex, and there are incon-
sistencies in results regarding ceramide  levels3. In this study we employed transgenic FAD mice with mutated 
APP/PSEN1 carrying human APOE4 or APOE3 replacement genes. In these transgenic models, the sphingolipid 
metabolome was never studied before.
Bandaru et al. reported that APOE4 is associated with sphingolipid disbalance only in patients with underly-
ing neurological  disorders17. AD patients carrying APOE4 variants displayed elevation of ceramides d18:1/18:0 
and d18:1/24:1 in the gray matter of the middle frontal gyrus (MFG) and of ceramide d18:1/22:0 in the white 
matter of the MFG when compared to AD patients carrying APOE3. SM d18:1/22:0 and SM d18:1/24:0 levels 
were reduced in the MFG gray matter while no difference in SM levels were found in the MFG gray matter. In 
this work, mass spectrometry analysis on the hippocampus, containing both white and gray matter, showed 
that APOE4 carriers have higher levels of ceramide d18:1/16:0, which is then reduced in FAD mice. Notably, we 
reported a substantial increase across almost all monohexyl-ceramide species analyzed in the mice with APOE4 
Figure 6.  [18F]F-HPA-12 radioactivity correlates with Cer d18:1/20:2 levels but not with CERTs concentration 
in the hippocampus. (A) Fluorescent HPA-12 (HPA-12-NBD) chemical structure. Image was drawn using 
BKChem Wiki 0.13.0 (URL: https ://bkche m.zirae l.org/wiki/doku.php?id=avail able_packa ges&rev=12717 
65119 ) Visualization of HPA-12-NBD in hippocampal lipid extract, separated by TLC. Bar graph represent 
quantification in percentage of intact HPA-12-NBD of 2 controls and 2 FAD brains. (B) CERTs measured in 
hippocampal protein extract by ELISA. Bars represent the means ± S.E.M of control (APOE3 N = 4; APOE4 
N = 6) and FAD (E3FAD N = 4; E4FAD N = 5). (C) Correlation between Cer d18:1/20:2 and CERT concentration 
quantified by ELISA in the hippocampus. (D) Correlation between radioactive counts and CERT concentration 
quantified by ELISA in the hippocampus. (E) Correlation between radioactive counts and Cer d18:1/20:2 levels 
in the hippocampus measured by LC-ESI/MS/MS. (F) Correlation between radioactive counts and astrogliosis 
measured by immunostaining in the hippocampus. A color code was given too each genotype. All correlation 
are based on number of XY Pairs = 17.
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background compared to APOE3 background independently of being FAD mice. This observation could be 
related to the different glucose metabolism that has been reported in these transgenic  animals42. Nevertheless, the 
biggest difference in ceramide composition was found between carriers or non-carriers of APP/PSEN1 mutations. 
Statistical analysis considering APOE and AD genes as independent factors highlighted APP/PSEN1 genes to be 
the only independent factor to impact ceramides levels significantly and, in particular, Cer d18:1/20:2. Ceramide 
increases in the brains of AD patients and AD animal models and the reason as to why is still unbeknownst to us. 
However, the fact that transgenic animals with severe Aβ pathology show ceramide overproduction, suggests that 
it is a consequence of aberrant plaque formations in the brain. Recently, the contribution of activated astrocytes to 
ceramide elevation in the brains of AD patients has been  reported33. Activated astrocytes propagate Aβ in extra-
cellular vesicles and increase the toxicity of the peptide to neurons, as  well35,43. Here, we observed that activated 
astrocytes in FAD mice are associated with increased levels of ceramide, and that there is a correlation between 
densitometric analysis of GFAP immuno-labeling and Cer d18:1/20:2.Surprisingly, the radiotracer did not cor-
relate with CERTs concentration in the hippocampus. Genome-wide gene-expression analysis on amyloid mice 
models points to a constant reduction of CERTs protein expression after 4 months of age in the hippocampus, 
which becomes more relevant at 18 months of age. In our study, we did not find differences in CERTs protein 
levels by ELISA in 8–9 months old females. However, CERTs levels correlated with Cer d18:1/20:2 levels. This 
implies that while the CERTs concentration is not enough to explain the differences in uptake of the radiotracer 
in the hippocampus, it still has a biological association to Cer d18:1/20:2 elevation in FAD mice. In the future, 
the generation of CERT knock-out mouse will be helpful to determine if the uptake of the tracer depends on 
CERT levels or function. In fact the metabolic changes of the tracer in the brain may depend on the efficiency 
of CERT transport. Therefore an impaired CERT transport would result in slower  [18F]F-HPA-12 metabolism.
The muscles were the only other organ that showed a difference in uptake of the radiotracer dependent on 
the FAD genotype. The idea that AD pathophysiology affects neurons and muscles similarly is not  surprising44. 
Mariani et al. showed an increase of oxidative enzyme activity in muscles of AD patients. Other studies reported 
that AD hallmarks like Aβ plaques and tau fibrils could be found in the muscle linking peripheral muscle degen-
eration to neuronal pathology in the brain of AD  patients44–46. The high uptake of  [18F]F-HPA-12 in the muscle 
strengthens the idea that the tracer specifically detects AD pathology. Nevertheless, we do not know if higher 
uptake in the muscles is caused by an increase in ceramide levels.
Even though  [18F]F-HPA-12 was able to accurately differentiate between FAD mice and the control with a sen-
sitivity of 85.7% and a specificity of 87.5%, proposing  [18F]F-HPA-12 as a diagnostic tool in AD is still premature. 
The study has some limitations. The first limitation is the lipophilic nature of the radiotracer which remains a 
limiting factor, due to the incredibly slow clearance from the brain and the possibility of high unspecific bind-
ing. One hour post-injection the plateau of the slope for  [18F]F-HPA-12 uptake in the brain, is still not reached. 
An analog tracer with similar properties but with faster uptake and brain clearance, would be desirable. There 
are other ceramide analogs with more hydrophilic nature that could be used for this  purpose28. Secondly, the 
animals were tested when the Aβ pathology is exceptionally severe and blood–brain barrier damage (BBB) could 
have occurred. The FAD mice might show BBB damage after 9 months47,48. The APOE4 genotype is sufficient 
to cause damage to BBB vasculature and function, potentially before the age of 12 months, as  well49. However, 
we did not observe a difference in uptake between APOE4 carriers and APOE3 suggesting that BBB damage is 
not affecting  [18F]F-HPA-12 brain kinetics, in this instance. Also note, the differences in uptake were specific 
for brain regions like the hippocampus and striatum but not for cerebellum. A study including younger animals 
should be conducted at the initial stages of the disease. The study should be addressed prior to envisioning the 
tracer for diagnostic aims. These contributions will help prove a relevant approach. The third limitation is the 
metabolic analysis which was performed on a limited number of animals, and we did not determine the identity 
of the HPA-12 metabolites. We were not able to exclude the possibility that the metabolic changes are happening 
when crossing the BBB and what we are observing is difference in dynamic BBB crossing of the HPA-12, either.
In summary, we pioneered a new method to study sphingolipid metabolism in the brain using a ceramide 
analog, which can cross the blood–brain barrier and accumulate in the brain. This preliminary study opens a 
new avenue for compound mimicking sphingolipid structure to study sphingolipid disbalance in the brain and 
potentially to diagnose diseases by PET.
Material and methods
Radiotracer preparation. [18F]F-HPA-12 was prepared as previously  described29. HPLC purification 
(1.0 mL/min, solvent A; 0.1% TFA in water, solvent B;  CH3CN) (95% to 0% A in 15 min, 0% A to 25 min) was 
performed on a Shimadzu UFLC HPLC system equipped with a DGU-20A5 degasser, a SPD-M20A UV detec-
tor, a LC-20AT pump system, a CBM-20A communication BUS module, and a Scan-RAM radio-TLC/HPLC-
detector from LabLogic using an Aeris Widepore column (XB-C18, 3.6 μm, 4.6 mm × 250 mm). A collected 
fraction was evaporated and re-suspended in vehicle solution PEG400/PBS 1:4 (V/V) previously sterilized by 
filtration and pH adjusted to 7.4. To dissolve the compound completely, the preparation was warmed up to 37 °C 
and vortexed vigorously.
Experimental design and animals. The transgenic mice, E3FAD and E4FAD, were purchased from Dr. 
Mary Jo LaDu (The University of Illinois; Chicago) and bred in-house as described  elsewhere30. E3FAD and 
E4FAD were generated by backcrossing the 5xFAD mice which carries human APP and PSEN1 genes with 5 
mutations (APP KM670/671NL (Swedish), APP I716V (Florida), APP V717I (London), PSEN1 M146L (A > C), 
PSEN1 L286V)50 to the APOE-targeted replacement mice, in which the murine APOE gene locus is replaced 
with the human APOE3 or APOE4 gene. Therefore, E3FAD and E4FAD are homozygous for the APOE3 and 
APOE4 allele respectively and hemizygous for the APP/PSEN1 genes.[18F]HPA-12 was tested on 9–12 month 
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old transgenic female E4FAD and E3FAD, as FAD mice, and littermate non-carriers of mutated APP/PSEN1 
genes (referred to as APOE3 and APOE4) as control animals. Animal weight is reported in Supplementary 
Fig. 1B. All experiments were approved by the Animal Welfare Committee of Maastricht University and followed 
the laws, rules, and guidelines of the local and national authorities of the Netherlands.
PET imaging. APOE4, APOE3 (referred to as control), E4FAD and E3FAD (referred to as AD) animals 
8–9 months old were anesthetized using a continuous isoflurane (2.5% in  O2) anesthesia protocol. Body tem-
perature was monitored and maintained using an electrical heating pad during the same time. After intravenous 
injection of 1.8 MBq of radiotracer  [18F]F-HPA-12 was administered, animals were positioned supine, and data 
was acquired, continuously, for 1 h. PET images were acquired using a Siemens MicroPET Focus 120 (Siemens 
Healthcare) with an axial field of view (FOV) of 7.6 cm and a spatial resolution of about 1.3 mm. The data which 
was collected was corrected for dead time, random coincidences, and decay. Images were reconstructed using 
OSEM2D. PET images were analyzed with PMOD 3.7 software. A mouse CT scan was used to define volumes of 
interest (VOIs) for heart, liver, left kidney and total brain. Time activity curves (TACs) were generated by apply-
ing VOIs to the dynamic PET images. TACs were normalized to injected activity and body weight to obtain an 
outcome measure of standardized uptake value (SUV). Tomographic images were co-registered with the Mir-
roine mouse T2-MRI template to mask the activity outside the brain. We report the average results of PET slices 
from 47–60 min  acquisition51,52.
[18F]F‑HPA‑12 Biodistribution and metabolism. Biodistribution and metabolism analysis was per-
formed as we previously  described29. One and half hour post-injection, the mice were terminally anesthetized. 
Prior to intra-cardial profusion, blood and urine were collected from the mice. Next in the procedure, the brain, 
skin, eyes, spleen, intestines, liver, stomach, kidneys, lungs, bones, muscles and heart organs were dissected from 
the animal. The half-brain was further micro-dissected into the brain stem, cerebellum, hippocampus, striatum, 
cortex, and bulbus. Radioactivity content of all dissected body parts was measured using a 2480 Wizard2 gamma 
counter (Perkin Elmer). The results were corrected for radioactive decay and expressed as a percentage of total 
injected dose per gram of tissue (% ID/g).
As previously mentioned, the radio-analytical studies were performed on urine, blood, and brain by  HPLC29. 
HPLC elution from 0–1 min, 2–4 min, 12–14 min, and 16–18 min were collected and measured on a gamma 
counter. At each retention time we expected to elute the following: background radioactivity, free fluorine-18, 
undetermined metabolite, and intact  [18F]F-HPA-12, respectively.
Fluorescent HPA‑12 (HPA‑12‑NDB) brain metabolism. Fluorescent HPA-12 (HPA-12 NDB) was 
prepared for the first time as described in Supplementary Materials and Methods and Supplementary Figs. 2–5. 
HPA-12 NDB was used to study HPA-12 brain metabolism. About 6–12.5  µg/animal of HPA-12-NBD was 
injected IV in 5% ethanol in PBS vehicle (maximum volume injected was of 250 µL/animal). The animals were 
sacrificed as explained above. The hippocampus was isolated and homogenized in ice cold, high purity water 
and subjected to the Folch method lipid extraction. In brief, lipids were extracted from 400 µL homogenate 
by the addition of 1 mL of methanol (CH3OH) followed by the addition of 3 mL of chloroform (CHCl3) and 
sonicated for 10 min. High purity water (600 µL) was added and the sample sonicated for an additional 10 min. 
The samples were then centrifuged for 5 min at 2000×g and the organic phase was collected and dried under 
a nitrogen stream. The lipids were dissolved in 50 µL CH3OH and 5 µL extraction was separated by TLC with 
95:5 CHCl3:CH3OH. A dilution series of HPA-12-NBD was used as reference for sample migration. The gel was 
imaged with the Biorad ChemiDOC system. The complete image is reported in Supplementary Fig. 6A.
Autoradiography. An hour and a half post-injection, the brains were isolated after perfusion, as explained 
above. The hemibrain was embedded in optimal cutting temperature (OCT) and frozen in liquid nitrogen. The 
brains were then sectioned in a cryostat with a thickness of 16 µm and mounted-on microscope slides. Once 
dried, brain sections were incubated in phosphor film overnight. Finally, the film was read on the Typhoon FLA 
7000 (Perkin Elmer). Images were processed by applying Gaussian blur and printed identically with  ImageJ53.
Brain protein extraction. Brain protein extractions were performed on dissected hippocampus, since a 
bigger difference in uptake was measured in this brain region. After gamma counter analysis, the hippocampus 
was powdered with an iron mortar partly emerged in liquid nitrogen and divided into aliquots. One aliquot was 
further lysed in 0.1% SDS, 0.1% Triton X-100, 1% glycerol, 1 mM EDTA, 1 mM EGTA, PhosSTOP and protein 
inhibitors (Roche). Total protein content was determined with the Bio-Rad DC (Life Science Group) protein 
assay following the manufacturer’s instructions.
ELISA for CERT detection. Polyclonal antibodies anti-CERTs used in this assay, polyclonal rabbit 01 
(Rb01) and polyclonal rabbit 02 (Rb02) were produced by EUROGENTEC SA Immunization Department 
based on the purified full-length human protein (recombinant  hCERTL, 1875 bp NP_005704.1)54. Validation 
of antibodies was performed by coating microplates with 25 ng of recombinant CERTs, produced as previously 
 explained54. Then a dilution series (1:900, 2700, 8100, 24,300, 72,900) of the antibodies IgG purified from serum, 
was applied to the wells. After addition of anti rabbit-biotinylated and streptavidin-HRP (Jackson ImmunoRe-
search Laboratories Europe Ltd.), signal was developed using 3,3′,5,5′-Tetramethylbenzidine (TMB). Absorp-
tion was measured at 450 nm within 30 min of stopping the reaction with 2 M  H2SO4 using the Perkin Elmer 
2030 manager system. The detection curve is reported in Supplementary Fig. 6B. For CERT detection in brain 
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samples, microplates were coated with 100 μL of Rb01 diluted to a final concentration of 5 μg/mL using coating 
buffer (50 mM carbonate/bicarbonate buffer pH 9.6), sealed with a plastic sticker and incubated for 1 h at 37 °C. 
The standard curve was made with serial dilutions of recombinant CERTs diluted in 10% BSA, 0.02% Tween-
20 in PBS (a detection curve is reported in Supplementary Fig. 6C). Biotinylated Rb02 was used as detection 
antibody diluted to final concentration 5 μg/mL, in 1% BSA and 0.02% Tween-20 in PBS and incubated for 
1 h at 37 °C. The Rb02 was biotinylated with an EZ-Link Sulfo-NHS-LC-Biotin kit (ThermoFisher), following 
company recommendations. Finally, plates were incubated with streptavidin-HRP and developed using TMB. 
Absorption was measured as stated above.
Immunofluorescent staining. After perfusion, half-brains were moved sequentially into 4% paraform-
aldehyde and 30% sucrose before embedding them in OCT and freezing them. The brains were sectioned in 
cryostat at 30 µm thickness and mounted on microscope glasses and stored in − 20 before immunofluorescent 
staining. After air drying for 30 min, the sections were rehydrated with PBS and stained with 0.5% Thioflavin S 
prepared in aqueous solution for 8 min at room temperature. Sections were then washed in 70%, 95% ethanol, 
distilled water and PBS. Then sections were blocked for 2 h with 3% BSA in PBS and incubated overnight with 
rabbit anti-ceramide (1:500 dilution)55 and mouse anti-Glial fibrillary acidic protein (GFAP) 1:200 (2E1, Santa 
Cruz). The next day, after 3 step washing in PBS, the sections were incubated with secondary antibodies don-
key anti-rabbit Alexa-649 and goat anti-mouse Cy3 for 1 h at room temperature. Pictures were acquired with a 
fluorescent microscope, Eclipse Ti2-E inverted microscope system (Nikon). Images were processed using Nikon 
NIS-Elements AR software 5.02.00 equipped particle density analyzer. Graphs and statistics are based on the 
average of two independent stainings.
Lipidomics analysis. Lipid extraction. Tissues were homogenized with a Precellys 24 in 800 μL of wa-
ter, of which 700 μL was mixed with 800 μL 1 N HCl:CH3OH 1:8 (v/v), 900 μL CHCl3 and 200 μg/ml of the 
antioxidant 2,6-di-tert-butyl-4-methylphenol (BHT; Sigma Aldrich). 3 μL of SPLASH LIPIDOMIX Mass Spec 
Standard (#330707, Avanti Polar Lipids) was added into the extract mix. The organic fraction was evaporated 
using a Savant Speedvac spd111v (Thermo Fisher Scientific) at room temperature and the remaining lipid pellet 
was stored at − 20 °C under  argon56.
Mass spectrometry. Mass spectrometry was performed as previously  described56. Lipid pellets were recon-
stituted in 100% ethanol. Lipid species were identified and measured by liquid chromatography electrospray 
ionization tandem mass spectrometry (LC-ESI/MS/MS) on a Nexera X2 UHPLC system (Shimadzu), coupled 
with hybrid triple quadrupole/linear ion trap mass spectrometer (6500 + QTRAP system; AB SCIEX). Chroma-
tographic separation was performed on an XBridge amide column (150 mm × 4.6 mm, 3.5 μm; Waters) main-
tained at 35 °C using mobile phase A [1 mM ammonium acetate in water-acetonitrile 5:95 (v/v)] and mobile 
phase B [1 mM ammonium acetate in water-acetonitrile 50:50 (v/v)] in the following gradient: (0–6 min: 0% 
B to 6% B; 6–10 min: 6% B to 25% B; 10–11 min: 25% B to 98% B; 11–13 min: 98% B to 100% B; 13–19 min: 
100% B; 19–24  min: 0% B) at a flow rate of 0.7  mL/minutes which was increased to 1.5  mL/minutes from 
13 min onwards. SM, CE, CER, DCER, HCER, LCER were measured in positive ion mode with a precursor 
scan of 184.1, 369.4, 264.4, 266.4, 264.4 and 264.4 respectively. TAG, DAG and MAG were measured in posi-
tive ion mode with a neutral loss scan for one of the fatty acyl moieties. PC, LPC, PE, LPE, PG, PI, PS were 
measured in negative ion mode by fatty acyl fragment ions. Lipid quantification was performed by scheduled 
multiple reactions monitoring (MRM), the transitions being based on the neutral losses or the typical product 
ions as described above. The instrument parameters were as follows: Curtain Gas = 35 psi; Collision Gas = 8 a.u. 
(medium); IonSpray Voltage = 5500 V and − 4,500 V; Temperature = 550 °C; Ion Source Gas 1 = 50 psi; Ion Source 
Gas 2 = 60 psi; Declustering Potential = 60 V and − 80 V; Entrance Potential = 10 V and − 10 V; Collision Cell Exit 
Potential = 15 V and − 15 V.
The following fatty acyl moieties were taken into account for the lipidomic analysis: 14:0, 14:1, 16:0, 16:1, 
16:2, 18:0, 18:1, 18:2, 18:3, 20:0, 20:1, 20:2, 20:3, 20:4, 20:5, 22:0, 22:1, 22:2, 22:4, 22:5 and 22:6 except for TAGs 
which considered: 16:0, 16:1, 18:0, 18:1, 18:2, 18:3, 20:3, 20:4, 20:5, 22:2, 22:3, 22:4, 22:5, 22:6.
Lipidomics data analysis. Peak integration was calculated with the MultiQuant software version 3.0.3. Lipid 
species signals were corrected for isotopic contributions (calculated with Python Molmass 2019.1.1) and were 
quantified based on internal standard signals and adheres to the guidelines of the Lipidomics Standards Initia-
tive (LSI) (level 2 type quantification as defined by the LSI).
Statistical analysis. The statistical analysis was performed using RStudio 1.2.503357, IBM SPSS statis-
tic version 26, or GraphPad Prism version 8.4.3 (686). Matrices of the ceramides, SM, dihydroceramide, and 
monohexyl-ceramides for the hierarchical cluster analysis and heatmaps were generated with RStudio. The four 
classes of sphingolipids ceramides, SM, dihydroceramide, and monohexyl-ceramides were further analyzed by 
multivariate analysis with SPSS with APOE and FAD genes (APP/PSEN1) as independent factors. When Wilks’ 
Lambda test was found significant, MANOVA was followed by a series of ANOVA for each acyl-chain species, 
and LSD was used for post hoc testing eventually. Biodistribution data were analyzed using two-way ANOVAs, 
with APOE genes and AD genes as independent factors; the LSD post hoc test was used for multiple compari-
sons. A p-value of < 0.05 was considered significant. Time activity curves for the brain, liver, heart, kidneys, and 
lungs were acquired with PMOD2 as previously  described29, and were tested for statistical differences between 
AD and littermate controls by comparing the Vmax or Km of the best fit values calculated with the Michae-
lis–Menten kinetic model. A Pearson or Spearman correlation was used to determine the relationship between 
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radiotracer activity in the brain and CERT relative quantification, and the four sphingolipid species under inves-
tigation mentioned above. The diagnostic performance and accuracy of  [18F]HPA-12 were also evaluated using 
Receiver Operating Characteristic (ROC) curve  analysis34.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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